Please use this identifier to cite or link to this item: https://doi.org/10.1002/mgg3.313
DC FieldValue
dc.titleClinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing
dc.contributor.authorChew, W.H.W
dc.contributor.authorCourtney, E
dc.contributor.authorLim, K.H
dc.contributor.authorLi, S.T
dc.contributor.authorChen, Y
dc.contributor.authorTan, M.H
dc.contributor.authorChung, A
dc.contributor.authorKhoo, J
dc.contributor.authorLoh, A
dc.contributor.authorSoh, S.Y
dc.contributor.authorIyer, P
dc.contributor.authorLoh, L.M
dc.contributor.authorNgeow, J
dc.date.accessioned2020-11-17T06:37:13Z
dc.date.available2020-11-17T06:37:13Z
dc.date.issued2017
dc.identifier.citationChew, W.H.W, Courtney, E, Lim, K.H, Li, S.T, Chen, Y, Tan, M.H, Chung, A, Khoo, J, Loh, A, Soh, S.Y, Iyer, P, Loh, L.M, Ngeow, J (2017). Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing. Molecular Genetics and Genomic Medicine 5 (5) : 602-607. ScholarBank@NUS Repository. https://doi.org/10.1002/mgg3.313
dc.identifier.issn2324-9269
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/183555
dc.description.abstractBackground: Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors of the adrenal glands and paraganglia, occurring sporadically or as a range of hereditary tumor syndromes. About 30% of PPGLs are attributed to germline mutations. Clinical presentation, including localization, malignant potential, and age of onset, varies depending on the genetic background. Genetic testing for PPGLs is not well studied in Southeast Asia. We reviewed clinical management of PPGLs in Singapore, highlighting current gaps in clinical practice. Methods: Medical records of patients with PPGLs between 2005 and 2016 were reviewed. Diagnosis was confirmed histologically and stratified into sporadic or familial/syndromic (FS). Results: Twenty-seven (21.8%) patients were referred to the Cancer Genetics Service (CGS). FS PPGLs (18.5%) and extra-adrenal PPGLs (58.1%) incidences were higher than previous studies. Referrals were lower for sporadic PPGLs compared to FS PPGLs (3.7% vs. 100%). Referrals were highest at diagnosis age <20 years old (80%) and decreased with increasing age; ?20–<40 years old (32.1%), ?40–<60 years old (10.6%). Genetic testing was taken up in 12/27 (44.4%) patients of which 7/12 (58.3%, 3 SDHB, 2 SDHD, 2 VHL) had germline mutations. Conclusion: Opportunities for genetic testing are frequently missed due to low referral rates in patients with apparently sporadic PPGLs, particularly between ages 20-60. © 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
dc.publisherWiley Blackwell
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1002/mgg3.313
dc.description.sourcetitleMolecular Genetics and Genomic Medicine
dc.description.volume5
dc.description.issue5
dc.description.page602-607
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1002_mgg3_313.pdf226.79 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

2
checked on May 15, 2021

Page view(s)

55
checked on May 13, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons